Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer
about
PDX1 associated therapy in translational medicineWhole Tumor Antigen Vaccines: Where Are We?Novel Furin Inhibitors with Potent Anti-infectious ActivityDysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor ImmunityCurrent status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.Repression of liver colorectal metastasis by the serpin Spn4A a naturally occurring inhibitor of the constitutive secretory proprotein convertases.Proprotein convertase inhibition: Paralyzing the cell's master switches.Effect of survivin on tumor growth of colorectal cancer in vivo.Generation and characterization of non-competitive furin-inhibiting nanobodies.Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNAPilot Trial of FANG Immunotherapy in Ewing's Sarcoma.Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer.Design of Effective Primary MicroRNA Mimics With Different Basal Stem Conformations.Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.T-cell-expressed proprotein convertase FURIN inhibits DMBA/TPA-induced skin cancer development.Myeloid cell expressed proprotein convertase FURIN attenuates inflammation.The proprotein convertase furin is required to maintain viability of alveolar rhabdomyosarcoma cells.siRNA and cancer immunotherapy.Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.Insights into the Transforming Growth Factor-β Signaling Pathway in Cutaneous Melanoma.Transfer and Expression of Small Interfering RNAs in Mammalian Cells Using Lentiviral VectorsVertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform.Therapeutic uses of furin and its inhibitors: a patent review.The Role of the Immune System in Ovarian Cancer and Implications on Therapy.A multiplexed miRNA and transgene expression platform for simultaneous repression and expression of protein coding sequences.Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions.Pancreatic cancer actionable genes in precision medicine and personalized surgery.Keratin 17 is co-expressed with 14-3-3 sigma in oral carcinoma in situ and squamous cell carcinoma and modulates cell proliferation and size but not cell migration.Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines.Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.Prodomain of the proprotein convertase subtilisin/kexin Furin (ppFurin) protects from tumor progression and metastasis.Preclinical Biodistribution and Safety Evaluation of a pbi-shRNA STMN1 Lipoplex after Subcutaneous Delivery.The proprotein convertase furin in tumour progression.Gli1, a potential regulator of esophageal cancer stem cell, is identified as an independent adverse prognostic factor in esophageal squamous cell carcinoma.Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine.The Plasma Level of Proprotein Convertase FURIN in Patients with Suspected Infection in the Emergency Room: A Prospective Cohort Study.Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.Cancer targeting vaccines: surrogate measures of activity.Knockdown and replacement therapy mediated by artificial mirtrons in spinocerebellar ataxia 7.Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease.
P2860
Q26744079-B57E02C8-93B3-4796-AC00-015B6F3DBAFEQ26783866-89FF44B1-5214-4444-ACBB-4D8A90F3D2B9Q27700845-CE4D9949-4382-4AA7-B7F1-C521E4797952Q28075996-C899F6D3-90C5-4593-A2D1-2EDDD764D891Q30412300-CD7430B9-92A9-411D-ABEE-515C9F2CA7CFQ34100905-DADACC1D-5F7B-4E4A-927F-0745FD9E4895Q36358957-4CAEB31D-5E00-4370-A3EB-71BF0F3F156DQ36375407-5FFDF27D-2993-41FC-AAAF-C96F1ABE7ACFQ36533737-EA1BDB68-FFDE-4C62-B531-BE4A1F09FFD1Q36694820-90A1CB79-3C32-4DDE-AC29-747481F2E1BBQ36756669-2B3C6F7F-8152-4D16-8B2B-D0C34D4370BCQ36756699-8069FB38-5285-47D9-B9E4-DE2532552D3FQ37234566-8D8EA7FB-86C7-48C3-B7B7-33580885A25DQ37256170-A8499A96-C2AB-45BB-AEFC-7E107397EF69Q37558166-BC7D8ECC-E86D-4CF6-A7B4-8078816F2C0AQ37688070-D7D5B83B-9E96-4A37-9F51-104842CF5E53Q37718282-D9E8FE09-30E3-491E-AF87-726BA030447CQ38050504-19CBF028-3D54-42B0-8E0B-90A80CE07CB5Q38109960-2FDE2643-5BB7-4F36-BFC5-3D5223E23B53Q38110273-894A4B6A-CB6B-465E-B2B6-A8CA292617BDQ38118762-5F1754A9-AD70-44E8-A1E1-B233A5E8D37FQ38181359-C5CADF28-60EE-4DBA-933F-3ACC6BD6950BQ38309128-810360CB-C05B-40DD-803F-7333E4E6DFC6Q38715211-2101D68A-73E6-4304-9B01-92B24DB8336CQ38815929-298924AA-0C01-4A3D-A537-EC8A7991E71BQ38828624-B640C2E9-7859-4A90-9513-183A638D04E0Q38884916-83E70146-E631-4D69-B209-76DC3F6FB568Q38903950-7FC6F500-BD65-4D71-AD7F-72743CE5EEFDQ38936958-2E7CB383-4D8C-424E-9566-8625F8743F6FQ39002223-2C4965DC-0BFB-4B87-95DF-0DF4487FA33BQ39078284-38D58794-A254-4BAB-B16E-36D3C6A9E8ECQ39213655-BFFF480C-7F82-40F7-B79F-A4E5810F33DAQ39215671-FED19617-ED38-4997-BD43-DCF7A462A517Q39343598-202E1FB1-E98C-4223-81B1-A8CE4AB353DEQ39456127-548795EB-7702-477D-8138-FC1FDDEF7BA5Q41011643-2C8008A2-2D86-4066-93F6-050094365954Q41093026-BFE2143C-6528-422D-9816-19AC70358FCFQ41222516-F423F522-1187-40A6-AC25-8AD0205F7C40Q41508524-819FB1DE-DD6E-4AB1-9C2A-6518CE1E413FQ42006104-5C3826AC-C077-46DF-A8C4-367A2B2CAE86
P2860
Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase I trial of "bi-shRNAi(fu ...... cine (FANG) in advanced cancer
@ast
Phase I trial of "bi-shRNAi(fu ...... cine (FANG) in advanced cancer
@en
Phase I trial of "bi-shRNAi(fu ...... cine (FANG) in advanced cancer
@nl
type
label
Phase I trial of "bi-shRNAi(fu ...... cine (FANG) in advanced cancer
@ast
Phase I trial of "bi-shRNAi(fu ...... cine (FANG) in advanced cancer
@en
Phase I trial of "bi-shRNAi(fu ...... cine (FANG) in advanced cancer
@nl
prefLabel
Phase I trial of "bi-shRNAi(fu ...... cine (FANG) in advanced cancer
@ast
Phase I trial of "bi-shRNAi(fu ...... cine (FANG) in advanced cancer
@en
Phase I trial of "bi-shRNAi(fu ...... cine (FANG) in advanced cancer
@nl
P2093
P2860
P3181
P356
P1433
P1476
Phase I trial of "bi-shRNAi(fu ...... cine (FANG) in advanced cancer
@en
P2093
Anton Melnyk
Beena O Pappen
Candice Higgs
Chris M Jay
Connor Phalon
Cynthia Bedell
David M Shanahan
Donald D Rao
F Charles Brunicardi
Fabienne Norvell
P2860
P304
P3181
P356
10.1038/MT.2011.269
P407
P577
2012-03-01T00:00:00Z